Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary W Redman

Showing results (11-20 of 86) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2012
Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819Mary W Redman, John J Crowley, Roy S Herbst, et al.
Urologic Oncology|July 22, 2023
Racial and sex differences in tumor genomics in urothelial carcinomaYaw A Nyame, Kelsey K Baker, Bruce Montgomery, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approachMary W Redman, Catherine M Tangen, Phyllis J Goodman, et al.
Clinical Lung Cancer|November 2, 2013
Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implicationsDavid R Gandara, Tianhong Li, Primo N Lara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2008
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trialsPrimo N Lara, Mary W Redman, Karen Kelly, et al.
Journal of the National Cancer Institute|April 25, 2018
Response to H. Nabi et alTing-Yuan David Cheng, Amy K Darke, Mary W Redman, et al.
Clinical Lung Cancer|June 9, 2012
Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneityDavid R Gandara, Tianhong Li, Primo N Lara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 11, 2017
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905)Anne S Tsao, James Moon, Ignacio I Wistuba, et al.
Cancer|August 26, 2010
Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124Primo N Lara, Kari Chansky, Taro Shibata, et al.
Clinical Lung Cancer|October 27, 2015
Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) DatabasePrimo N Lara, James Moon, Mary W Redman, et al.
Pageof 9

Showing results (11-20 of 86) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2012
Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819Mary W Redman, John J Crowley, Roy S Herbst, et al.
Urologic Oncology|July 22, 2023
Racial and sex differences in tumor genomics in urothelial carcinomaYaw A Nyame, Kelsey K Baker, Bruce Montgomery, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approachMary W Redman, Catherine M Tangen, Phyllis J Goodman, et al.
Clinical Lung Cancer|November 2, 2013
Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implicationsDavid R Gandara, Tianhong Li, Primo N Lara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2008
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trialsPrimo N Lara, Mary W Redman, Karen Kelly, et al.
Journal of the National Cancer Institute|April 25, 2018
Response to H. Nabi et alTing-Yuan David Cheng, Amy K Darke, Mary W Redman, et al.
Clinical Lung Cancer|June 9, 2012
Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneityDavid R Gandara, Tianhong Li, Primo N Lara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 11, 2017
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905)Anne S Tsao, James Moon, Ignacio I Wistuba, et al.
Cancer|August 26, 2010
Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124Primo N Lara, Kari Chansky, Taro Shibata, et al.
Clinical Lung Cancer|October 27, 2015
Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) DatabasePrimo N Lara, James Moon, Mary W Redman, et al.
Pageof 9